All News

Frontline therapy for DLBCL is evolving with the integration of targeted and cellular therapies, demonstrating promising outcomes.

Tagraxofusp monotherapy in myelofibrosis shows symptom relief with manageable toxicity, as pharmacists can monitor capillary leak syndrome and cytopenias.

A multicohort analysis reveals that obesity substantially increases hospitalization and mortality risk across diverse infectious diseases.

Neurology CPAs let pharmacists speed multiple sclerosis therapy, order labs and meds, cut delays, boost adherence, and expand collaborative care.

Pembrolizumab in adjuvant NSCLC therapy can trigger central adrenal insufficiency with vague fatigue, nausea, and hyponatremia.

The FDA issued a drug safety communication regarding rare but severe pruritus associated with discontinuation of long-term use of cetirizine or levocetirizine.

Insulin costs soar despite a century of use—see how PBMs, rebates, and new policies shape access, and what pharmacists can do.

Sarah Nelson, PharmD, highlights how pharmacists are uniquely positioned to prevent heart disease by identifying cardiovascular risk early, improving medication adherence, and addressing lifestyle and social factors.

New clinical findings highlight promising strategies for treating aggressive central nervous malignancies.

TrumpRx offers select branded drugs at cash prices outside insurance, requiring pharmacists to guide patients on cost comparisons, coverage limitations, and safe medication management, according to Ronna Hauser, PharmD.

Reevaluating menopause hormone therapy myths, risks, timing, and access.

FDA accepts Iberdomide new drug application for relapsed or refractory multiple myeloma; pharmacists prepare for oral anti-CD38 combos, MRD-driven care.

Expanded Medicaid coverage has been linked to access to early diagnosis, timely treatment, and continuity of care in breast cancer.

Anne Cassity details the National Community Pharmacists Association's (NCPA's) next pharmacy benefit manager (PBM) reform priorities, focusing on fair pharmacy reimbursement and congressional scrutiny of health care consolidation and vertical integration.

Trusted pharmacist guidance, motivational interviewing, and evidence-based resources help parents make informed pediatric immunization decisions.

FDA approves difamilast (Adquey), a topical PDE4 inhibitor, expanding nonsteroidal options for mild to moderate atopic dermatitis in dermatology patients 2 years and older.

Allison Hill, PharmD, RPh, underscores how pharmacists can sustain vaccination momentum through community partnerships.

Serotonin transporter occupancy explains sertraline withdrawal symptoms and helps distinguish relapse.

The safety of IV push iron sucrose amid shortages and breakthroughs in BCMA bispecifics and menin inhibitors reshape myeloma and leukemia care.

A pressure vibration device can cut propofol injection pain in patients undergoing surgeries, matching low-dose ketamine without extra adverse events.

Derek Webb and Dennis Williams outline practical, patient-centered strategies pharmacists can use to personalize OTC allergy recommendations, explain nondrowsy antihistamines clearly, and deliver efficient counseling in busy community settings.

This century has seen a dramatic shortage of pharmacists, then a dramatic pullback, and now a selective shortage. Will artificial intelligence tip the scale? If so, in which direction(s) and which settings of care?

Pitolisant is now the first and only FDA-approved nonscheduled treatment for cataplexy in pediatric and adult patients with narcolepsy.

The FDA approves a once-monthly dosing schedule for amivantamab and hyaluronidase-lpuj to optimize administration and cut down infusion times.

Craig Beavers, PharmD, explores new phase 3 evidence on factor XIa inhibitors for secondary stroke prevention, highlighting OCEANIC-STROKE results, safety, and patient selection.

The biosimilar is a cost-effective treatment for patients with conditions caused by cancer treatment.

Joseph Saseen, PharmD, explains how population health strategies and team-based care create new opportunities for pharmacists to identify lipid treatment gaps and lead evidence-based ASCVD prevention.

Telehealth expands physical therapy and pharmacy support.